Voubs is for sale. Contact us!
0
active Contests
0
Total Contests
€ 0
Current best prize
0
Participants





For certain premenopausal women with a chronic, acquired, low-arousal sexual drive condition, the 5-HT receptor modulator flibanserin has been effective (HSDD).

In August 2015, flibanserin became one of the first drugs approved by the FDA for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). This drug was originally developed as an antidepressant, but it failed to show adequate efficacy in clinical studies, thus it was reformulated as a hypoactive sexual condition therapy. Flibanserin's method of action involves its tight affinity with 5-HTA1 and 5-HTA2 receptors, demonstrating agonist activity on 5-HTA1 and antagonist action on 5-HTA2, which decreases serotonin levels in the brain while boosting the amount of dopamine and norepinephrine neurotransmitters.